Balance Sheet
Accumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HUTCHMED (China) (HCM) Current Deferred Revenue: 2014-2025

  • HUTCHMED (China)'s Current Deferred Revenue fell 2.72% to $46.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $46.8 million, marking a year-over-year decrease of 2.72%. This contributed to the annual value of $13.3 million for FY2022, which is N/A change from last year.
  • Latest data reveals that HUTCHMED (China) reported Current Deferred Revenue of $46.8 million as of Q2 2025, which was down 2.72% from $48.2 million recorded in Q2 2024.
  • In the past 5 years, HUTCHMED (China)'s Current Deferred Revenue ranged from a high of $52.3 million in Q2 2023 and a low of $3.1 million during Q2 2022.
  • Moreover, its 3-year median value for Current Deferred Revenue was $48.2 million (2024), whereas its average is $49.1 million.
  • In the last 5 years, HUTCHMED (China)'s Current Deferred Revenue spiked by 1,575.13% in 2023 and then decreased by 7.87% in 2024.
  • Quarterly analysis of 4 years shows HUTCHMED (China)'s Current Deferred Revenue stood at $13.3 million in 2022, then soared by 1,575.13% to $52.3 million in 2023, then fell by 7.87% to $48.2 million in 2024, then decreased by 2.72% to $46.8 million in 2025.
  • Its Current Deferred Revenue stands at $46.8 million for Q2 2025, versus $48.2 million for Q2 2024 and $52.3 million for Q2 2023.